Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ernest Amegashie

Cardiovascular Disease Hagerstown, MD Medical Doctor

NPI 1881788677 CMS profile 84892

1219 Mount Aetna Rd, Suite 201, Hagerstown, MD 21742

Open in the dashboard

General payments

$5,429

334 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ernest Amegashie of Hagerstown, MD is reported in the CMS Open Payments database as having received $5,429 across 334 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 71st percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $569 29
2024 General $811 44
2023 General $895 47
2022 General $939 55
2021 General $857 75
2020 General $329 21
2019 General $1,031 63

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ernest Amegashie
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Ernest Amegashie were reported at $569. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Ernest Amegashie Cardiovascular Disease median Middle half National median
2019 $1,031 $450 $127–$1,392 $163
2020 $329 $242 $77–$751 $114
2021 $857 $335 $101–$1,037 $132
2022 $939 $395 $121–$1,211 $149
2023 $895 $443 $136–$1,283 $160
2024 $811 $450 $136–$1,323 $164
2025 $569 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Pharmaceuticals, Inc $653 32 payments
  2. Novartis Pharmaceuticals Corporation $618 39 payments
  3. Amgen Inc. $475 28 payments
  4. E.R. Squibb & Sons, L.L.C. $471 39 payments
  5. Merck Sharp & Dohme Corporation $441 27 payments
  6. Esperion Therapeutics, Inc. $358 20 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $322 17 payments
  8. Kowa Pharmaceuticals America, Inc. $301 34 payments
  9. Pfizer Inc. $257 16 payments
  10. Amarin Pharma Inc. $254 15 payments
  11. Other $1,279 67 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,417 333 payments
  2. Education $12 1 payment
Products named General payments · program years 2019–2025
  1. XARELTO $653 32 payments
  2. VERQUVO $513 31 payments
  3. Repatha $429 26 payments
  4. ELIQUIS $382 36 payments
  5. NEXLETOL $358 20 payments
  6. Livalo $301 34 payments
  7. LEQVIO $280 16 payments
  8. ENTRESTO $253 19 payments
  9. LifeVest $250 14 payments
  10. JARDIANCE $220 12 payments
  11. Other $2,510 153 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 65 drugs

Part D claims

5,963

Median for Cardiology: 2,533

Drug cost

$1,311,166

Median for Cardiology: $485,213

Branded share of claims

28.7%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 502 $562,952
Xarelto Rivaroxaban Brand 259 $331,572
Entresto Sacubitril/Valsartan Brand 140 $183,729
Repatha Sureclick Evolocumab Brand 59 $50,146
Nexletol Bempedoic Acid Brand 36 $28,605
Verquvo Vericiguat Brand 17 $23,301
Brilinta Ticagrelor Brand 18 $21,397
Praluent Pen Alirocumab Brand 19 $12,817
Dabigatran Etexilate Dabigatran Etexilate Mesylate Brand 37 $10,320
Metoprolol Succinate Generic 681 $9,283

The 10 drugs with the highest cost, of 65 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 34 billing codes

Paid by Medicare

$514,208

Of which drugs: $3,017

Medicare patients

1,686

Average age 76

Services billed

6,952

923 women, 763 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Ischemic heart disease 49%
Diabetes 36%
Atrial fibrillation 24%
Chronic kidney disease 22%
Depression 21%
COPD 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 141 568 $3,017

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NEXLETOL
  • Esperion Therapeutics, Inc. $101
$101 36 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $97
$97 — —
VERQUVO
  • Merck Sharp & Dohme Corporation $72
$72 17 —
XARELTO
  • Janssen Pharmaceuticals, Inc $67
$67 259 —
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $34
  • PFIZER INC. $23
$57 502 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

334 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record